Sugi Predict

Sugi Predict / Compounds / SCHEMBL242273

SCHEMBL242273

SCHEMBL242273

Cc1ccc(-c2ccc(C(=O)O)o2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.70
▸ HPGD P15428 4/20 0.70
▸ KDM4E B2RXH2 3/20 0.61
▸ MEN1 O00255 3/20 0.60
▸ KMT2A Q03164 3/20 0.60
▸ DDAH1 O94760 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ PDE4B Q07343 4/20 0.54
▸ PDE4D Q08499 2/20 0.54
▸ RPA1 P27694 1/20 0.53
▸ NQO2 P16083 1/20 0.53
▸ NR4A1 P22736 1/20 0.51
▸ NR4A2 P43354 1/20 0.51
▸ NR4A3 Q92570 1/20 0.51
▸ MGAM O43451 2/20 0.51
▸ GAA P10253 2/20 0.51
▸ SI P14410 2/20 0.51
▸ MGAM2 Q2M2H8 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1772679 0.90 ALDH1A1 (0.84) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL12885825 0.83 ALDH1A1 (0.69) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL28511353 0.83 PDE4B (0.52) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL9613179 0.83 ALDH1A1 (0.68) ALDH1A1HPGDKDM4EKMT2ARPA1
SCHEMBL307282 0.82 ALDH1A1 (0.92) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL2557432 0.81 ALDH1A1 (0.66) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL4896906 0.81 ALDH1A1 (0.66) ALDH1A1HPGDKDM4ECYP1A2CYP2C19
SCHEMBL4943742 0.81 HTT (0.51) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL25275688 0.81 ALDH1A1 (0.71) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL3054179 0.81 ALDH1A1 (0.70) ALDH1A1HPGDKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11424006-B2 Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide PSOMAGEN, INC. (US) 2022-08-23 — — US claimed
US-20210128498-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE MACROGEN INC. (KR) 2021-05-06 — — US claimed
EP-3668494-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE Psomagen, Inc. (US) 2020-06-24 — — EP claimed
CN-111163761-A Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide 普梭梅根公司 2020-05-15 — — CN claimed
WO-2019036507-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE uBiome, Inc. (US) 2019-02-21 — — WO claimed
US-20190050525-A1 RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES PSOMAGEN, INC. 2019-02-14 — — US claimed
US-7109243-B2 Inhibitors of cathepsin S IRM LLC (BM) 2006-09-19 — — US claimed
US-20060052365-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2006-03-09 — — US claimed
JP-2006505526-A — — 2006-02-16 — — JP claimed
EP-1539178-A2 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2005-06-15 — — EP claimed
WO-2004017911-A2 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-03-04 — — WO claimed
US-11424006-B2 Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide PSOMAGEN, INC. (US) 2022-08-23 — — US disclosed
US-20220202772-A1 COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2022-06-30 — — US disclosed
US-20210128498-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE MACROGEN INC. (KR) 2021-05-06 — — US disclosed
US-20210128498-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE MACROGEN INC. (KR) 2021-05-06 — — US disclosed
EP-1419161-A1 SUBSTITUTED-HETEROARYL-7-AZA 2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-05-19 — — EP disclosed
WO-2004017911-A2 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-03-04 — — WO disclosed
US-6562816-B2 Alpha 7 nicotine acetylcholine receptor agonist anti-psychotic agent, with reduced side effects PHARMACIA & UPJOHN COMPANY 2003-05-13 — — US disclosed
US-20030069290-A1 SUBSTITUTED-HETEROARYL-7-AZA[2.2.1] BYCYCLOHEPTANES FOR THE TREATMENT OF DESEASE PHARMACIA & UPJOHN COMPANY 2003-04-10 — — US disclosed
WO-2003018585-A1 SUBSTITUTED-HETEROARYL-7-AZA[2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2003-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202772-A1 COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS RACK1, RRBP1, RPL30 ALDH1A1 3524/4885HPGD 3417/4885KDM4E 2155/4885
US-11424006-B2 Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide PNMT, MAOA, HNMT ALDH1A1 988/4885HPGD 3530/4885KDM4E 733/4885
US-20210128498-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE MAOA, PNMT, HNMT ALDH1A1 959/4885HPGD 3494/4885KDM4E 1224/4885
US-20030069290-A1 SUBSTITUTED-HETEROARYL-7-AZA[2.2.1] BYCYCLOHEPTANES FOR THE TREATMENT OF DESEASE SULT1E1, UGT1A7, UGT1A1 ALDH1A1 1238/4885HPGD 1427/4885KDM4E 112/4885
US-20060052365-A1 Protease inhibitors CTSS, CTSE, CMA1 ALDH1A1 1528/4885HPGD 1420/4885KDM4E 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.